{"id":4966,"date":"2016-08-09T12:12:04","date_gmt":"2016-08-09T12:12:04","guid":{"rendered":"http:\/\/polymax.bg\/%d0%b8%d0%bc%d1%83%d0%bd%d0%be%d1%82%d0%b5%d1%80%d0%b0%d0%bf%d0%b8%d1%8f-%d1%81-%d0%bf%d0%be%d0%bb%d0%b8%d0%bf%d0%b5%d0%bf%d1%82%d0%b8%d0%b4%d0%b8-%d0%bf%d0%be%d0%bb%d0%b8%d0%bc%d0%b0%d0%ba%d1%81\/"},"modified":"2020-06-25T21:28:58","modified_gmt":"2020-06-25T21:28:58","slug":"additional-information-for-medical-specialists","status":"publish","type":"page","link":"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/","title":{"rendered":"Additional information for medical specialists"},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4966","page","type-page","status-publish","post-password-required","hentry","has-post-title","has-post-date","has-post-category","has-post-tag","has-post-comment","has-post-author",""],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Additional information for medical specialists &#8226; NORMACELL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Additional information for medical specialists &#8226; NORMACELL\" \/>\n<meta property=\"og:description\" content=\"There is no excerpt because this is a protected post.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/\" \/>\n<meta property=\"og:site_name\" content=\"NORMACELL\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-25T21:28:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/normacell.ch\\\/en\\\/additional-information-for-medical-specialists\\\/\",\"url\":\"https:\\\/\\\/normacell.ch\\\/en\\\/additional-information-for-medical-specialists\\\/\",\"name\":\"Additional information for medical specialists &#8226; NORMACELL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/normacell.ch\\\/en\\\/#website\"},\"datePublished\":\"2016-08-09T12:12:04+00:00\",\"dateModified\":\"2020-06-25T21:28:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/normacell.ch\\\/en\\\/additional-information-for-medical-specialists\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/normacell.ch\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/normacell.ch\\\/en\\\/\",\"name\":\"NORMACELL\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/normacell.ch\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Additional information for medical specialists &#8226; NORMACELL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/","og_locale":"en_GB","og_type":"article","og_title":"Additional information for medical specialists &#8226; NORMACELL","og_description":"There is no excerpt because this is a protected post.","og_url":"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/","og_site_name":"NORMACELL","article_modified_time":"2020-06-25T21:28:58+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/","url":"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/","name":"Additional information for medical specialists &#8226; NORMACELL","isPartOf":{"@id":"https:\/\/normacell.ch\/en\/#website"},"datePublished":"2016-08-09T12:12:04+00:00","dateModified":"2020-06-25T21:28:58+00:00","breadcrumb":{"@id":"https:\/\/normacell.ch\/en\/additional-information-for-medical-specialists\/#breadcrumb"},"inLanguage":"en-GB"},{"@type":"WebSite","@id":"https:\/\/normacell.ch\/en\/#website","url":"https:\/\/normacell.ch\/en\/","name":"NORMACELL","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/normacell.ch\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"builder_content":"<h2>NORMACELL and oncology<\/h2>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<p style=\"text-align: justify;\">The treatment of cancer in humans is a complex science still not fully understood in all its aspects. At every stage of the illness and during the therapy - which is a heavy burden both for the patient and their relatives - a product supporting the basic therapy can be very useful. The peptides in NORMACELL have been used for more than 40 years in the adjuvant treatment of tumors.<\/p> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] NORMACELL stabilizes the immune system.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] NORMACELL increases patient\u2019s survival and quality of life.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] NORMACELL improves the tolerance to chemotherapy.<\/h5> <p style=\"text-align: justify;\">The reliable efficacy of the peptides in the product has been proven in numerous controlled studies. NORMACELL contains biogenic peptides derived from swine spleen through standardized procedures. Permanent high quality and safety of the product are the basis of NORMACELL production. NORMACELL provides the necessary support for the specialist and the patient in their fight against cancer.<\/p>\n<p style=\"text-align: justify;\">The treatment of cancer in humans is a complex science still not fully understood in all its aspects. At every stage of the illness and during the therapy - which is a heavy burden both for the patient and their relatives - a product supporting the basic therapy can be very useful. The peptides in NORMACELL have been used for more than 40 years in the adjuvant treatment of tumors.<\/p> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] NORMACELL stabilizes the immune system.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] NORMACELL increases patient\u2019s survival and quality of life.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] NORMACELL improves the tolerance to chemotherapy.<\/h5> <p style=\"text-align: justify;\">The reliable efficacy of the peptides in the product has been proven in numerous controlled studies. NORMACELL contains biogenic peptides derived from swine spleen through standardized procedures. Permanent high quality and safety of the product are the basis of NORMACELL production. NORMACELL provides the necessary support for the specialist and the patient in their fight against cancer.<\/p>\n<h4>Toxicological assessment<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<h3 style=\"text-align: justify;\">Acute toxicity<\/h3> <p style=\"text-align: justify;\">In an effort to determine the LD 50% of the preparation a single intramuscularly administered dose of &gt; 20 ml \/ kg of body weight in rats did not cause death of any animal. The dose used was more than 500 times higher than the clinical dose. There was only a slight hyperexcitability and weak tonic cramps in the first three hours after the application.<\/p> <h3 style=\"text-align: justify;\">Chronic toxicity<\/h3> <p style=\"text-align: justify;\">Doses of 0.4, 1.0 and 2.0 ml \/ kg, administered intramuscularly to Wistar rats, 6 times a week for 13 weeks, and doses of 0.32 and 0.8 ml \/ kg in dogs every day for 3 months did not cause changes in mortality, weight and nutrition of the animal. There were no changes in response of erythrocyte sedimentation or in biochemical tests of blood and urine. There were no changes in organic weight and histology.<\/p> <p style=\"text-align: justify;\">There were no mutagenic changes in vitro from the peptides used in NORMACELL.<br \/>No carcinogenicity has been observed.<br \/>There was no pyrogenicity.<\/p> <p style=\"text-align: justify;\"><strong>In summary, the testing of the peptides in NORMACELL on mice, rats, rabbits and dogs has not shown any undesired pharmacological or toxic effects.<\/strong><\/p>\n<h3 style=\"text-align: justify;\">Acute toxicity<\/h3> <p style=\"text-align: justify;\">In an effort to determine the LD 50% of the preparation a single intramuscularly administered dose of &gt; 20 ml \/ kg of body weight in rats did not cause death of any animal. The dose used was more than 500 times higher than the clinical dose. There was only a slight hyperexcitability and weak tonic cramps in the first three hours after the application.<\/p> <h3 style=\"text-align: justify;\">Chronic toxicity<\/h3> <p style=\"text-align: justify;\">Doses of 0.4, 1.0 and 2.0 ml \/ kg, administered intramuscularly to Wistar rats, 6 times a week for 13 weeks, and doses of 0.32 and 0.8 ml \/ kg in dogs every day for 3 months did not cause changes in mortality, weight and nutrition of the animal. There were no changes in response of erythrocyte sedimentation or in biochemical tests of blood and urine. There were no changes in organic weight and histology.<\/p> <p style=\"text-align: justify;\">There were no mutagenic changes in vitro from the peptides used in NORMACELL.<br \/>No carcinogenicity has been observed.<br \/>There was no pyrogenicity.<\/p> <p style=\"text-align: justify;\"><strong>In summary, the testing of the peptides in NORMACELL on mice, rats, rabbits and dogs has not shown any undesired pharmacological or toxic effects.<\/strong><\/p>\n<h4>Biological activity<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">Several studies have established the following properties of NORMACELL:<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Through inhibition of glycolysis and lactic acid formation, the peptides in NORMACELL exhibit a growth-inhibiting activity over tumor cells.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL inhibit the growth of various tumor cell lines in vitro (colon carcinoma HT 129 and cell lines of small cell lung cancer - SCLC).<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL inhibit in vivo the growth of tumor cell lines of murine fibrosarcoma, melanoma B-16 and others.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL cause immunomodulation, evidenced by: E-rosette-forming assay; test of blast transformation of lymphocytes in mice immunosuppressed with 5-Fluorouracil (5-FU); in mice immunized with sheep erythrocytes and possess immunizing properties in mice infected with lethal doses of influenza virus.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL stimulate the proliferative response of lymphocytes: there is increased activity of cytotoxic T-lymphocytes and stimulation of cytokines in mice treated with cyclophosphamide.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL stimulate the release of gamma interferon from peripheral mononuclear cells in cancer patients.<\/p>\n<p style=\"text-align: justify;\">Several studies have established the following properties of NORMACELL:<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Through inhibition of glycolysis and lactic acid formation, the peptides in NORMACELL exhibit a growth-inhibiting activity over tumor cells.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL inhibit the growth of various tumor cell lines in vitro (colon carcinoma HT 129 and cell lines of small cell lung cancer - SCLC).<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL inhibit in vivo the growth of tumor cell lines of murine fibrosarcoma, melanoma B-16 and others.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL cause immunomodulation, evidenced by: E-rosette-forming assay; test of blast transformation of lymphocytes in mice immunosuppressed with 5-Fluorouracil (5-FU); in mice immunized with sheep erythrocytes and possess immunizing properties in mice infected with lethal doses of influenza virus.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL stimulate the proliferative response of lymphocytes: there is increased activity of cytotoxic T-lymphocytes and stimulation of cytokines in mice treated with cyclophosphamide.<\/p> <p style=\"text-align: justify;\">[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The peptides in NORMACELL stimulate the release of gamma interferon from peripheral mononuclear cells in cancer patients.<\/p>\n<h4>EFFECTIVENESS IN VITRO<\/h4><h3>Peptides in NORMACELL decrease of the growth of tumor cells<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-1-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">The peptides in NORMACELL significantly suppress cell growth of the colon carcinoma cell line HT-29 and the cell carcinoma of the liver on line BEL-7402. Development of the cells is blocked on phase GO \/ G1. Effect on the energy of the cell has been proven. (Organogen 1985a \/ Sun Yet-Se University 1995)<\/p>\n<h4>EFFECTIVENESS IN VITRO<\/h4> <h3>Stimulation of lymphocyte proliferation<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">The peptides in NORMACELL stimulate the proliferation of ConA-treated lymphocytes. This effect cannot be achieved by NORMACELL peptides separately, which is an indication that the immune system cannot be excessively stimulated (as in the case of lecithins). (Organogen 1985b).<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-2-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<h4>EFFECTIVENESS IN VIVO AND EX VIVO<\/h4><h3>Improved lymphocyte response after treatment with NORMACELL peptides<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-3-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">T-cells and cells of the spleen of mice which have received NORMACELL peptides i.p. (intra peritoneal) over a period of 14 days showed significantly increased secretion of IL-2 and IL-3, or g-IFN in comparison with the placebo group. (Ojeda. 1994)<\/p>\n<h4>EFFECTIVENESS IN VIVO AND EX VIVO<\/h4> <h3>Improves the immunity during treatment with 5-FU<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">Mice who received in advance orally NORMACELL peptides show significant improvement of their immune status after treatment with 5-Fluorouracil (5-FU) in comparison with the placebo group. The number of B- and T-cells in the marrow is significantly higher compared to placebo. (Orpegen, 1989)<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-4-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<h4>EFFECTIVENESS IN VIVO<\/h4> <h3>Prolongation of survival after infection with influenza - A virus<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-5-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">After pretreatment with the peptides in NORMACELL (p.o. and i.p.), mice infected with virus influenza-A (A \/ PRB \/ 34 H1N1) show significantly longer survival compared to placebo. (Van't Veen 1996)<\/p>\n<h4>EFFECTIVENESS IN VIVO<\/h4> <h3>Reduction in formation of lung metastasis in melanoma<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">In comparison with placebo, peptides in NORMACELL (i.p.) lead to a significant reduction in the number of metastases in mice after injection of cells from Melanoma B16. The combination of NORMACELL peptides (i.p.) with the cytostatic Dacarbazine (DTIC) increases this effect. Similar results are obtained by using cells of breast cancer from guinea pigs and Endotreksan as a chemotherapeutic. (Jurin 1996a. Zarkoric 1998)<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-6-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<h4>EFFECTIVENESS IN VIVO<\/h4><h3>Dose-dependent effect of NORMACELL peptides (oral and parenteral)<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-7-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">The formation of metastases of B16 melanoma in mice after administration of solution of the peptides in NORMACELL (p.o., i.p.) is significantly reduced. A dose dependent effect has been observed and the optimal dose can be determined. The optimal dose for oral administration is 5 mg \/ kg \/d. The dosage corresponds to the recommended oral dosage for humans. (Jurin 1996b, 1997, Zarkovic 1995, 1998)<\/p>\n<h2>CONCLUSION ON THE RESULTS OF IN VITRO AND IN VIVO STUDIES<\/h2>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The growth of tumor cells and metastases is reduced.<br \/><\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Lymphocyte proliferation and lymphocyte response are enhanced.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Immune status is improved.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Survival after infection with influenza A virus is increased.<\/h5>\n<h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] The growth of tumor cells and metastases is reduced.<br \/><\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Lymphocyte proliferation and lymphocyte response are enhanced.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Immune status is improved.<\/h5> <h5>[wp-svg-icons wrap=\"i\" icon=\"checkmark\" size=\"1em\" color=\"#e41d24\"] Survival after infection with influenza A virus is increased.<\/h5>\n<h4>CLINICAL EFFICACY<\/h4> <h3>Application in gastric carcinoma: a randomized, controlled, double-blind study<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-8-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">After a prior surgical treatment of 40 patients with gastric cancer (especially T3 and T4) 20 of them were subjected to long-term therapy with peptides in NORMACELL and 20 patients with liver extract. The group with peptdies used in NORMACELL had received the product daily for a period of 6 weeks, followed by administration every 2 days for a period of 1 year. The monitored 5 year survival was 44% in the group of the peptides in NORMACELL compared to 11% in the control group. (Klose 1977)<\/p>\n<h4>CLINICAL EFFICACY<\/h4> <h3>Application in breast cancer: a controlled, open study<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-9-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">After tumor specific pretreatment, 158 patients with breast cancer were divided in two groups: receiving peptides used in NORMACELL and a control group (79 + 79). The group with NORMACELL peptides received the recommended dose of NORMACELL peptide tablets (3 x 1) for a period of 6 weeks. The control group received vitamins and minerals. After 6 weeks the number of lymphocytes, Multitest Meryo, Index Zersen and Karnofsky index were significantly improved. The figure shows the percentage improvement in comparison with the control group. (Berressem 1995)<\/p>\n<h4>CLINICAL EFFICACY<\/h4> <h3>Survival in metastatic colon cancer: a randomized, controlled, double-blind study<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-10-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">Two clinical centers were included in this study with patients suffering from metastatic carcinoma of the colon. The figure shows the results from one of the centers. 20 of the patients received NORMACELL peptides in recommended dosage for 16 weeks and another 20 received placebo. Simultaneously both groups received the additional chemotherapy with leucovorin \/ 5-Fluorouracil. Patients had a significantly increased survival in the group with peptides used in NORMACELL. (Llliger 1998 \/ Klingmuller 1998a)<\/p>\n<h4>CLINICAL EFFICACY<\/h4> <h3>Lymphocytes in patients with cancer: a randomized, controlled, double-blind study<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-11-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">The study included 43 patients suffering of bronchial tumors and tumors of the gastrointestinal tract after tumor specific treatment. 22 patients received peptides used in NORMACELL in recommended dosage for 12 weeks, and 21 patients received placebo. Statistically there was significant therapeutic effect in the group with NORMACELL peptides: the lymphocyte count is improved (p = 0.01). The lymphocyte count decreased gradually in the placebo group. (Lindeiiiann 1998 \/ Westerhausen 1997)<\/p>\n<h4>CLINICAL EFFICACY<\/h4> <h3>Lymphocytes in tumors of the head and the neck: a randomized, controlled, double-blind study<\/h3>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12.png\" alt=\"\" width=\"1166\" height=\"1260\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12.png 1166w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12-139x150.png 139w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12-278x300.png 278w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12-768x830.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12-948x1024.png 948w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12-300x324.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/charts-en-12-600x648.png 600w\" sizes=\"auto, (max-width: 1166px) 100vw, 1166px\" \/><\/p>\n<p style=\"text-align: justify;\">The study included 40 patients with inoperable tumors of the head and the neck. 20 of the patients received peptides that are used in NORMACELL for a total of 25 weeks, while 20 patients received placebo. During this time four cycles of chemotherapy (Cisplatin \/ Carboplatin - \/ - Floruratsil) have been made. Patients from the group with NORMACELL peptides showed less weight loss and a significantly lesser degree of fatigue (p = 0.03) for the whole period of treatment. Within their group the lymphocyte count was more stable during the chemotherapy as well and was significantly higher after the 25th week. Kinetic behavior of lymphocytes correlates with the kinetic behavior of the levels of fatigue. (Borghardt 1995, 2000)<\/p>\n<h4>PRODUCT DESCRIPTION<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">NORMACELL contains natural biogenic peptides obtained from swine spleen through a patented, certified and standardized process. Purification of the substance used in the capsules provides an enriched peptide fraction.<\/p> <p>Production of NORMACELL is performed under strict quality control. Each package is controled several times before release.<\/p> <p>The manufacturer has passed DIN EN ISO 9001-2008 certification. This way our customers get permanently high and reliable quality products.<\/p>\n<p style=\"text-align: justify;\">NORMACELL contains natural biogenic peptides obtained from swine spleen through a patented, certified and standardized process. Purification of the substance used in the capsules provides an enriched peptide fraction.<\/p> <p>Production of NORMACELL is performed under strict quality control. Each package is controled several times before release.<\/p> <p>The manufacturer has passed DIN EN ISO 9001-2008 certification. This way our customers get permanently high and reliable quality products.<\/p>\n<h4>COST OF THE THERAPY<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">The cost of the long-term treatment with NORMACELL peptides is less than 25% of the average cost of any anti-cancer therapy. The peptides in NORMACELL support the success of the therapy and has proven effectiveness.<\/p>\n<p style=\"text-align: justify;\">The cost of the long-term treatment with NORMACELL peptides is less than 25% of the average cost of any anti-cancer therapy. The peptides in NORMACELL support the success of the therapy and has proven effectiveness.<\/p>\n<h4>PRODUCT SAFETY<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">NORMACELL peptides are used for more than 40 years in the adjuvant therapy of tumor diseases. During this period no adverse events have been reported.<\/p> <p>During the manufacturing process of NORMACELL peptides only natural ingredients of animal (swine) origin are used, while the additional materials are either of mineral or of vegetal origin.<\/p> <p>The risk of transmission of viral or other pathogenic agents from the raw material is excluded by several independent validation processes.<\/p> <p>All the toxicological studies (acute toxicity, chronic toxicity, teratogenicity, mutagenicity) have demonstrated the safety of the product.<\/p> <p>No allergic or anaphylactic reactions have been observed after administration of the peptides used in NORMACELL. Potentially allergenic proteins are neutralized during the manufacturing process.<\/p>\n<p style=\"text-align: justify;\">NORMACELL peptides are used for more than 40 years in the adjuvant therapy of tumor diseases. During this period no adverse events have been reported.<\/p> <p>During the manufacturing process of NORMACELL peptides only natural ingredients of animal (swine) origin are used, while the additional materials are either of mineral or of vegetal origin.<\/p> <p>The risk of transmission of viral or other pathogenic agents from the raw material is excluded by several independent validation processes.<\/p> <p>All the toxicological studies (acute toxicity, chronic toxicity, teratogenicity, mutagenicity) have demonstrated the safety of the product.<\/p> <p>No allergic or anaphylactic reactions have been observed after administration of the peptides used in NORMACELL. Potentially allergenic proteins are neutralized during the manufacturing process.<\/p>\n<h4>USAGE<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">It is recommended the treatment to be continued for a longer period of time (at least 6 months) but optimally one year. Patients with cancer should consider taking it for lifetime.<\/p> <p>The optimal success of the therapy can be achieved when it is started as soon as possible after the diagnosis of the disease. Administration of NORMACELL peptides should be coordinated with the physician in charge.<\/p>\n<p style=\"text-align: justify;\">It is recommended the treatment to be continued for a longer period of time (at least 6 months) but optimally one year. Patients with cancer should consider taking it for lifetime.<\/p> <p>The optimal success of the therapy can be achieved when it is started as soon as possible after the diagnosis of the disease. Administration of NORMACELL peptides should be coordinated with the physician in charge.<\/p>\n<h4>USAGE<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p style=\"text-align: justify;\">It is recommended the treatment to be continued for a longer period of time (at least 6 months) but optimally one year. Patients with cancer should consider taking it for lifetime.<\/p> <p>The optimal success of the therapy can be achieved when it is started as soon as possible after the diagnosis of the disease. Administration of NORMACELL peptides should be coordinated with the physician in charge.<\/p>\n<p style=\"text-align: justify;\">It is recommended the treatment to be continued for a longer period of time (at least 6 months) but optimally one year. Patients with cancer should consider taking it for lifetime.<\/p> <p>The optimal success of the therapy can be achieved when it is started as soon as possible after the diagnosis of the disease. Administration of NORMACELL peptides should be coordinated with the physician in charge.<\/p>\n<h4>BROCHURE<\/h4>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png\" title=\"normacell-16-mobile\" alt=\"normacell-16-mobile\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile.png 375w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-300x12.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-mobile-150x6.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\n<img src=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png\" title=\"normacell-16\" alt=\"normacell-16\" srcset=\"https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16.png 1600w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-300x3.png 300w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1024x10.png 1024w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-150x1.png 150w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-768x7.png 768w, https:\/\/normacell.ch\/en\/wp-content\/uploads\/normacell-16-1536x14.png 1536w\" sizes=\"(max-width: 1600px) 100vw, 1600px\" \/>\n<p>[pdf id=6140]<\/p>","_links":{"self":[{"href":"https:\/\/normacell.ch\/en\/wp-json\/wp\/v2\/pages\/4966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/normacell.ch\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/normacell.ch\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/normacell.ch\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/normacell.ch\/en\/wp-json\/wp\/v2\/comments?post=4966"}],"version-history":[{"count":0,"href":"https:\/\/normacell.ch\/en\/wp-json\/wp\/v2\/pages\/4966\/revisions"}],"wp:attachment":[{"href":"https:\/\/normacell.ch\/en\/wp-json\/wp\/v2\/media?parent=4966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}